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 INTRODUCTION 
India has the third highest number of estimated people living with HIV in the world. 
National adult (15-49 years) HIV prevalence is estimated at 0.26%(0.22% to 0.32%) 
in 2015. The prevalence of HIV among males is 0.30% and among females is 0.22%. 
Among the states, Manipur remains the highest estimated HIV prevalence of 1.15% 
followed by Mizoram (0.8%), Nagaland (0.78%). Tamil nadu shows HIV prevalence 
greater than national prevalence (0.26%). 
 
The cost of combination ART has dropped in recent years as a result of generic 
medicines and differential pricing based on country need and ability to pay. The cost 
of diagnostic services to determine eligibility for treatment and to monitor treatment 
response has kept ART inaccessible to many. The US Department of Health and 
Human services (DHHS) and the World Health Organisation (WHO) recommend 
initiating ART therapy based on consideration of a patient‘s CD4 T cell count when 
available. 
 
The cost of monitoring HIV therapy may become more prohibitive than the cost of 
medications themselves. In December 2003, the WHO broadened the 
recommendations for initiation of ART when CD4 testing is unavailable to include 
WHO stage III or IV or WHO stage II in combination with a TLC 1200 cells/cu.mm. 
Many studies have evaluated the use of TLC as a surrogate marker for CD4 cell count 
with mixed results. Some studies have found a good relation but others have not. In  
 addition to low lymphocyte count ,anemia , thrombocytopenia have been associated 
with advanced HIV infection. 
 
―The initiation of ART is based upon CD4 count <350 cells among patients in clinical 
staging1 and 2 according to NACO. The determination of CD4 count requires highly 
skilled laboratory personnel, sophisticated equipments which is difficult in resource 
limited localities. So the role of ALC and TLC in place of CD4 count is being studied 
and various cut offs have emerged. Many studies have suggested the use of ALC as a 
sensitive marker for HIV progression. Also,studies have demonstrated the usefulness 
of ALC or TLC in identifying patients who would benefit from initiating prophylaxis 
for AIDS related opportunistic infections‖. 
 
―The purpose of this dissertation is to assess the capability and clinical utility of TLC 
change to serve as a surrogate marker for CD 4 count change in monitoring patients, 
which has important implications for resource-limited settings. We are correlating 
CD4 Count to Total Lymphocyte Count, which is available in all resource limited 
settings as it is obtained by multiplying Total Leucocyte Count and percentage of 
Lymphocyte in Differential Count, to monitor disease progression in HIV infected 
persons‖   
 
―This dissertation is also an attempt to look into the correlation between hemoglobin 
and progression of the disease, which is monitored by change in CD 4 count . Since  
 our study is being done in the resource poor set-up, the observations and conclusions 
can be used for monitoring progression of disease in HIV infected persons in our own 
set-up as well as other resource limited settings‖.   
 
REVIEW OF LITERATURE 
 
 
―AIDS is a retroviral disease caused by the Human immunodeficiency virus (HIV). It 
is characterised by infection and depletion of CD4 T lymphocytes , and by profound 
immune suppression leading to opportunistic infections , secondary neoplasm and 
neurological manifestations. Although AIDS was first described in the United States , 
it has now been reported in virtually every country in the world. Worldwide, more 
than 22 million people have died of AIDS since the epidemic was recognised in 1981 ; 
about 42 million people are living with the disease , and there are an estimated 5 
million infections each year‖.         
                                                                                        
 
 
 
 
 
 
 
 
  
 
 
 
 
 EPIDEMOLOGY OF HIV IN INDIA 
 
―India has a population of more than 1 billion people. Although only about 0.7% of its 
population is infected with HIV, it has more cases than any other country in the world, 
with more than 4.5 million HIV-seropositive patients. The epidemic of HIV/AIDS in 
India is distributed between the urban and rural populations mainly in the southern 
and western states of the country‖ 
 
 India has several different epidemics in various parts of the country. The epidemic in 
the western and southern states is primarily heterosexual. The north eastern states of 
India, being in geographical proximity to the Golden Triangle of Asia, initially 
experienced HIV in the injection drug user population and their sexual partners, but 
spread to the heterosexual population has been increasing. At present, the northern 
states, which are the most densely populated, appear to remain largely unaffected by 
the HIV epidemic.                                                                                                                                  
India has mounted a broad intervention program, including the government, and 
international, nongovernmental, and community-based organizations. The main 
barriers to effective control are insufficient resources, illiteracy, and stigma. 
Antiretroviral drugs are manufactured in the country and exported elsewhere, but their 
affordability (despite a drastic reduction in costs) and the feasibility of monitoring 
patients on drugs are in question. 
HIV is the etiologic agent of AIDS; it belongs to the family of human retroviruses 
(Retroviridae) and the subfamily of lentiviruses.The four retroviruses known to cause 
human disease belong to two distinct groups: the human T lymphotropic viruses 
(HTLV)-l and HTLV-2,which are transforming retroviruses; and the human 
immunodeficiency viruses,HIV- 1 and HIV-2, which cause cytopathic effects either 
directly or indirectly.The most common cause of HIV disease throughout the world 
and certainly in the United Statesis HIV- 1. The currently defined groups of HIV - 1 
(M,N,O, P) and the HIV-2 groups A through H each are likely derived from a separate 
transfer to humans from a nonhuman primate reservoir. HIV -1 viruseslikely came 
from chimpanzees and/or gorillas, and HIV-2 from sooty mangabeys. The AIDS  
  
 
 
 
 
 
pandemic is primarily caused by the HIV- 1 M group viruses. HIV-2 causes a similar 
disease principally in West Africa. Specific tests for HIV-2 are now available, and 
blood collected for transfusion is also routinely screened for HIV-2 seropositivity. 
 
 
MORPHOLOGY OF HIV 
 
 
― HIV virion is an icosahedral structure containing numerous external spikes formed 
by the two major envelope proteins,the external gp 120 and the transmembrane gp4 1 . 
The HIV envelope exists as a trimeric heterodimer. The virion buds from the surface 
of the infected cell and incorporates a variety of host proteins into its lipid. The virus 
core contains (1)major capsid protein p24, (2) nucleocapsid protein p7/p9, (3) two 
copies of genomic RNA , and (4) three viral enzymes (protease, reverse transcriptase ,  
and integrase).p24 is the most readily detected viral antigen and is therefore the target 
for the antibodies used to diagnose HIV infection in blood screening . the viral core is 
surrounded by a matrix protein called p17 , lying beneath the virion envelope.‖ 
 
  
 
 
OUTSTANDING CHARACTERISTICS OF HIV: 
  
―Predominantly affected cell: cells involved in immune function. 
 
Permanent association of provirus within the infected cells. 
  
Expression of virus: restricted in some cells in vivo 
 
Long clinical latency: disease progresses very slowly  
 
Replication: species specific‖ 
 
 
 
 
 
  
 
HIV GENOME: 
―HIV genome comprises of 9 genes encoding 3 structural, 2 envelope, and 6 
regulatory proteins. It also consists of a homodimer of linear, positive-sense, single-
stranded RNA of approximately 9.2 kb in size. The key structural proteins are gag , 
pol ,env genes. The gag gene encodes the matrix. Nucleocapsid , capsid proteins. The 
pol gene encodes protease , reverse transcriptase and integrase. The env gene encodes 
a key‖  
 
 
 
 ―HIV surface antigen gp160 comprising of gp120 and gp41. The products of the gag 
and pol genes are translated initially into large precursor proteins that must be cleaved 
by the viral protease to yield the mature proteins.‖ 
―Regulatory genes containinformation required for the production of proteins that 
control HIV‘s ability to infect a cell, reproduce and cause disease. These are tat , rev, 
vif,nef,vpu,vpr. The tatgene  –transactivator of transcriptionis encoded by 2 different 
exons from multiply spliced mRNA. The 102 aminoacidtat is responsible for 
activation of viral transcription through TAR binding, which creates binding sites for 
RNA pol II and other cellular proteins. It initiates synthesis of full-length transcripts. 
Tat is secreted into the circulation thus a possibility for inhibition by antibodies. It can 
also be a target for CTLs. Tat structure is rather conserved varying only slightly 
among different clades. It is produced in excess in infected cells.Tat also induces 
apoptosis of T cells, even the uninfected ones. It has also been shown to act as a 
neurotoxin and give rise to cells causing Kaposi‘s sarcoma.‖ 
“The rev geneis essential accessory protein whose function is to transport mRNA to 
the cytoplasm. Rev is a 117 aaphosphoprotein that binds to RRE (cis-acting element) 
within the env gene of all unspliced mRNAs. The N-terminal nuclear localization 
signal (NLS) directs its import back into the nucleus. Rev-dependent export of viral 
RNA distinguishes b/w early and late phase‖.   
―The vif gene is viral infectivity factor required for infection of human lymphocytes 
and some cell lines. Its ORF overlaps with the 3‘ end of pol. A 23 kDa protein found 
in the cytoplasm and cell membrane. The mechanism of action is not well understood 
but its importance in maturation process is recognized as the infectivity of Vif 
defective virions produced in non-permissive cells can be 25-100 times lower than 
wild type. Vif has been found in virus particles at levels similar to Pol but since it is 
also present in murine leukemia virus, possible significance of Vif incorporation is to 
be determined‖.  
“The nef gene (negative factor) is a 27 kD determinant of progression to AIDS. It 
downregulates cell surface receptor expression, interferes with signal transduction 
pathways and enhances viral infectivity and production. Nef is post-translationally 
modified by phosphorylation and by the irreversible attachment of myristic acid to its 
N-terminus, which targets Nef to the cellular membrane. The most enigmatic HIV 
protein as its mechanisms of action are not well understood and many contradictory 
phenotypes have been associated with expression of Nef.‖  
“The vpu gene (viral protein U), is 81 aa membrane protein expressed as part of a 
bicistronic message also encoding Env and regulated by Rev. It promotes release of 
viral particles from plasma membrane of infected cell and degrades CD4in the 
endoplasmic reticulum. The ability to form a cation-selective ion channel has also 
been described as another function of Vpu but its role is not known.‖ 
“The vpr gene (viral protein R), is 96 aa, 14 kDa protein responsible for G2 cell cycle 
arrest thought to indirectly enhance viral replication by increasing transcription from 
LTR. Vpr expression causes breaks in the nuclear lamin structure, which weakens 
nuclear envelope and interferes with DNA synthesis thus cycle arrest prior to mitosis.  
 It is also implicated in facilitating infection of non-dividing cells, mostly 
macrophages. Vpr also functions to connect the pre-integration complex to the cellular 
nuclear import machinery.‖  
 
 
 
 
PROTEINS WITH ANTIVIRAL ACTIVITIES IN HUMAN CELLS 
1. APOBEC3G 
 
2. TRIM5α 
 
3. TETHERIN 
  
 
 
―APOBEC3G 
 It causes suppression of viral transcription. It acts on viral genome and 
substitute adenosine in the place of guanine in the viral genome. The virus can easily 
overcome its action by ubiquitinisation and degradation of the protein. This is carried 
out by vif gene‖. 
TRIM5α 
 ―This protein causes premature uncoating of viral nucleocapsid iin cellular 
cytoplasm itself. Virus evades this cellular antiviral mechanism by producing 
variation in capsid protein.‖ 
TETHERIN  
 ―This is a newly found molecule present in the host cytoplasm. It is otherwise 
called CD317. It inhibits budding of newly formed virus through cellular membrane. 
Viruses are sequestered in tetherin mediated vesicles. Action of tetherin is inhibited by 
increased production of vpu protein by the virus.‖ 
 
 
 MODES OF TRANSMISSION 
 
 
 
―HIV is transmitted primarily by sexual transmission both by heterosexual and male to 
male transmission,by blood products,and by infected mother to child or via breast 
milk.‖ 
 
 
SEXUAL TRANSMISSION 
―The most frequent mode of transmission of HIV is through sexual contact with an 
infected person. The majority of all transmissions worldwide occur through 
heterosexual.however, the pattern of transmission varies significantly among 
countries. In the United States, as of 2010, most common mode of transmission is 
male to male transmission. In India most common mode of transmission is through  
 heterosexual.Women of childbearing age are at particular risk for acquiring HIV  
through unprotected sex‖ 
―Risk of transmission increases in the presence of many sexually transmitted 
infections and genital ulcers .The viral load of infected person is an important risk 
factor in both sexual and mother-to-child transmission.The rate of HIV transmission is 
highest (twelve fold)during early stages of HIV infection.  If the person is in the late 
stages of infection, rates of transmission are approximately eightfold greater.‖ 
 
TRANSMISSION BY BLOOD AND BLOOD PRODUCTS  
―HIV can be transmitted to individuals who receive HIV tainted blood transfusions, 
blood products, or transplanted tissue as well as to IDUs who are exposed to HIV 
while sharing injections . It is estimated that >90% of individuals exposed to HIV 
contaminated blood products become infected. In some resource poor countries due to 
inadequate screening HIV continues to be transmitted by blood , blood products and 
tissues .‖  
OCCUPATIONAL TRANSMISSION OF HIV 
―Health care workers and laboratory personnel who are working with HIV containing 
materials are at risk. Exposures that place a health care worker at potential risk of HIV  
 
 infection are percutaneous injuries or contact of mucous membrane or nonintact skin 
with blood ,tissue or other infectious body fluids.‖  
TRANSMISSION BY ORGAN TRANSPLANTATION 
―Hiv transmission has been reported in all types of solid organ transplantion. Oragan 
donation by hiv patients has been prohibited world wide. There is growing debate to 
life this ban thereby allowing hiv‖ 
 
MATERNAL –FETAL/INFANT TRANSMISSION 
―HIV infection can be transmitted from an infected mother to her fetus during 
pregnancy,during delivery or by breast feeding. However , maternal transmission to 
the fetus occurs most commonly in the perinatal period. The risk factors for mother to 
child transmission of HIV via breast feeding are low maternal CD4 T cell count , 
maternal vitamin A deficiency, presence of HIV in breast milk, and presence of 
mastitis. The risk is highest during the early months of breast feeding.‖ 
 
TRANSMISSION BY OTHER BODY FLUIDS  
―The following fluids are considered infectious : cerebrospinal fluid , synovial fluid , 
pleural fluid, peritoneal fluid , pericardial fluid and amniotic fluid.‖ 
  
 
MODE OF HIV TRANSMISSION IN INDIA : 
 
 
 
LIFE CYCLE OF HIV: 
 
―The entry of HIV into the cells requires the CD4 molecule , which acts as a high 
affinity receptor for the virus. This explains the tropism of the virus for CD4 +T cells 
,particularly macrophages and DCs. However , binding to CD4 is not sufficient for  
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 infection; the HIV envelope gp 120 must also bind to other cell surface molecules 
(coreceptors) to facilitate cell entry. Two cell surface chemokine receptors, CCR5 and 
CXCR4, serve this role.‖ 
 
 
 
 
―HIV envelope gp120 binds initially to CD4 molecule. This binding leads to a 
conformational change that exposes a new recognition site on gp120 for the CXCR4 
or CCR5 coreceptors. The gp41 then undergoes a conformational change that allows it 
to insert into the target membrane , and this facilitates fusion of the virus with the 
cell.‖  
―The coreceptors are critical components of the HIV infection process. HIV strains 
could be classified according to their relative ability to infect macrophages and/or 
CD4 T cells. Macrophage tropic (R5 virus) strains infect both 
monocytes/macrophages and freshly isolated peripheral blood T cells,whereas T cell 
tropic (X4 virus) strains infect only activated T cell lines.‖ 
 
 ―R5 strains use CCR5 as their coreceptor ,and.because CCR5 is expressed on both 
monocytes and T cells, these cells succumb to infection by R5 strains. Conversely , 
X4 strains bind to CXCR4 ,which is expressed on T cell lines , so that only activated 
T cells are susceptible‖. 
―Approximately 90% of HIV infections are initially transmitted by R5 strains. Over 
the course of infection, X4 viruses gradually accumulate . These are virulent and are 
responsible for T cell depletion in the final rapid phase of disease progression.‖ 
―During the course , R5 strains evolve into X4 strains , as a result of mutations in 
genes that encode gp120. The resultant transition in the ability of the virus to bind 
CXCR4 but not CCR5 is important in pathogenesis of AIDS because T tropic viruses 
are capable of infecting naïve T cells and thymic T cell precursor and cause greater T 
cell depletion and impairment.‖ 
―Once internalized , the viral genome undergoes reverse transcription leading to the 
formation of complementary DNA. In quiescent T cells , HIV proviralcDNA may 
remain in the cytoplasm in a linear episomal form. The cDNA enters the nucleus in 
dividing T cells and becomes integrated into the host genome. After  integration ,the 
provirus may remain non transcribed for months or years , and the infection becomes 
latent. Alternatively ,proviral DNA may be transcribed to form complete viral 
particles that bud from the cell membrane.‖ 
 
  
 
 
 
  
 
―Untreated HIV  infection results in the progressive loss ofCD4+ cells from the 
circulation as well asdepletion of CD4+ cells from total body. There are  several 
plausibletheories to explain the CD4+ cell depletionseen in HIV disease. CD4+ cells 
may be depleted because they are destroyed (the high-turnover model) or because 
their production is impaired (the regenerative failure model) .Another theory , holds 
that thefraction of circulating cells may decrease-- giving the appearance of loss—if 
HIV infection results in their redistribution out ofthe peripheral blood and into the 
confinesof lymphoid organs‖. 
 
―A critical distinction between the models for high turnover and regenerative failure is 
that the latter includes a primary pathogenic event in HIV disease that rests upon a 
failure to produce new CD4+ (and CD8+) cells . The modelspecifies that the sources 
of production—namely, the bone marrow, the thymus, and other extrathymic 
lymphoid organs(e.g., lymph nodes, spleen, and mucosa)—are rendered dysfunctional 
in later stages of  HIV disease, resulting in low (or no) rates of replacement in the face 
of continued CD4+ cell destruction. Over time, this imbalance leads to a decrease in 
the totalbody pool of mature T-cells and to immune system collapse, whether or not 
the destruction rate of CD4+ cells is accelerated. With the initiation of HAART, the 
viral assault on progenitor cells is halted, allowing for the production of new T-cells. 
Coupled with diminished destruction of mature T-cells, the CD4+ cell count rises.‖  
 
  
―When HIV is introduced into the body, it is probably concentrated with draining 
lymph nodes and presented as an antigen, resulting in enhanced movement of T-
cellsinto nodes and vigorous T-cell proliferation. The high turnover model holds that 
immune activation caused by HIV will be associated, by direct and indirect means, 
with accelerated destruction of T-cells and that the initiation of highly active 
antiretroviral therapyslows T-cell turnover and with it a decrease in the death rate of 
CD4+ cells. The regenerative failure model specifies that the source of T-cell 
productionnamely the bone marrow, the thymus, and other extrathymic lymphoid 
organs are rendered dysfunctional in later stages of HIV disease, resulting in low (or 
no) rates of replacement in the face of continued CD4+ cell destruction. Over time, 
this imbalance leads to a decrease in the total pool of mature T-cellsand to immune 
system collapse, whether or not the destruction rate of CD4+ cells is accelerated. With 
the initiation of HAART, the viral assault on progenitor cells is halted, allowing for 
the production of new T-cells. Coupled with diminished destruction of matureT-cells, 
the cd4+ cell count rises‖. 
 
 
 
 
 
 
  
 
 
ACCLERATED DESTRUCTION AND REGENERATIVE FAILURE MODELS OF 
HIV 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
DIAGNIOSIS OF HIV FUNCTION      
 ―HIV infection is identified either by the detection of HIV-specific antibodies 
in serum or plasma or by demonstrating the presence of the virus by nucleic acid 
detection using polymerase chain reaction (PCR), p24 antigen testing or, rarely these 
days, by growing virus in cell culture. Antibody testing is the method most commonly 
used to diagnose HIV infection. With the highly sensitive HIV-1/HIV-2 enzyme 
immunoassay (EIA) tests currently on the market, seroconversion can be detected 
within two to three weeks of infection in the majority of cases. In a small number of 
early seroconverters who are still in the 'window period', the p24 antigen may become 
positive before antibody is detectable. Therefore, to enable the laboratory to select 
appropriate testing, it is important to provide a clinical history that includes any recent 
high-risk behaviour or symptoms consistent with sero conversion illnes.‖ 
 ―All HIV diagnostic laboratories should confirm repeatedly positive EIA screen tests 
with another assay. The Western blot - the most commonly used confirmatory test - is 
a highly specific immunoblot that allows for the visualization of antibodies to the 
structural polypeptides of HIV. Some laboratories may use a radioimmuno 
precipitation assay as their confirmatory assay or as part of their HIV testing 
algorithm. In a radioimmunoprecipitation assay test, radiolabelled viral proteins are 
reacted with the patient's serum to produce radioactive antigen-antibody complexes.‖ 
 
 
                                                                                                                                                  
ANTIBODY DETECTION BY EIA 
 ―EIA is commonly used as a screening assay for HIV. These assays are used because 
they are highly sensitive and generally amenable to automation, facilitating high-
volume testing. HIV  This has shortened the 'window period', or the time from 
exposure to seroconversion, from up to 12 weeks or more in the early days of 
diagnostic testing to the current 'window period' of less than three weeks in most 
cases.‖ 
―The small disadvantage of such a highly sensitive test is that the test produces false 
positives, the number and type of which vary with the assay used and the HIV 
prevalence in the tested population. All HIV diagnostic laboratories must confirm 
repeated EIA screen-positive results by a confirmatory assay, usually with Western 
blot.‖ 
P24 ANTIGEN 
―p24 antigen tests are also EIA-based and use antibody to capture the disrupted p24 
antigen from patient serum. Positive results that are repeatable must be confirmed 
with a neutralization procedure. In rare instances, the p24 antigen can be detected 
before HIV antibody in newly infected individuals. This test is useful for specimens 
from patients that are high risk and symptomatic but HIV EIA-negative, or for 
specimens that are EIA-positive but Western blot-negative or -indeterminate . A 
follow-up HIV antibody test should be requested when a patient is p24 antigen-
positive but antibody-negative. In a seroconverting patient, the follow-up specimen 
will be positive within a few weeks after the initial screen. It is important to remember 
that not all seroconverting patients will have detectable p24 antigen, and that this 
antigen may not be reliably found in individuals who are known to be HIV antibody-
positive.‖ 
WESTERN BLOT                                                                                                                              
―The most commonly used confirmatory test is western blot. This assay takes 
advantage of the fact that multiple HIV antigens of different , well characterised 
molecular weights elicit the production of specific antibodies. These antigens can be 
separated on the basis of molecular weight, and antibodies to each component can be 
detected as discrete bands on the western blot.‖ 
 
LABORATORY MONITORING OF PATIENTS WITH HIV INFECTION 
―The close relationship between clinical manifestations of HIV infection and CD4 T 
cell has made measurement of the latter a routine part of the evaluation of HIV 
infected individuals. Determination of CD4 T cell count and measurements of the 
levels of HIV RNA in serum or plasma provide a powerful set of tools for determining 
prognosis and monitoring response to therapy.‖ 
 
 
 
CD4 CELL COUNT 
―CD 4 count analysis is the best indicator of the immediate state of immunological 
competence of the patient with HIV infection. This measurement , which can be made 
directly or calculated as the product of the percent of CD4 T cells (determined by flow 
cytometry) and the total lymphocyte count (determined by the white blood cell count 
(WBC) and the differential percent) has been shown to correlate well with the level of 
immunological competence.‖ 
―Patients with CD4 T cell count <200/µL are at high risk of disease from P.jiroveci , 
while patients with CD4 T cell count <50/µL are at high risk of disease from CMV , 
mycobacteria of the M.avium complex and/or T.gondii.‖ 
―Patients with HIV infection should have CD4 T cell measurement performed at the 
time of diagnosis and every 3-6 months thereafter. According to the guidelines, a CD4 
T cell count <350/µL is an indication for initiating ART treatment and decline in CD4 
T cell count of 25% is an indication for considering change in therapy.‖ 
―Patients with CD4 count <200/µL should be placed on prophylaxis regimen for 
P.jiroveci and once the count is <50/µL primary prophylaxis for MAC infection is 
indicated. In patients with hypersplenism or who have undergone splenectomy the 
CD4 cell percentage may be reliable than CD4 cell count. A CD4 cell percent of 15 is 
comparable to a CD4 T cell count of 200/µL.‖ 
 
 
 CD4 LEVELS IN RELATION TO SEVERITY OF IMMUNOSUPPRESSION 
Not significant immunosuppression >500 cells/µL 
Mild immunosuppression 350-499 cells/µL 
Advanced immunosuppression 200-349 cells/µL 
Severe immunosuppression <200 cells /µL 
 
HIV RNA DETERMINATIONS 
―HIV RNA measurements has become important component in the monitoring of 
patients with HIV infection. The two most commonly used techniques are the RT-
PCR assay and the bDNA assay. Quantitative RNA PCR must only be used to monitor 
HIV-positive individuals before or during antiretroviral therapy. It is used in 
conjunction with CD4 counts and general clinical assessments to ascertain when 
therapy should be started. It is also used to help determine the patient's response to 
therapy. Therapy should be considered in patients with >100,000 copies of HIV RNA 
per millilitre‖.  
 
―HIV RNA measurements are to be done frequently to monitor therapy , which has 
great economic burden to many people in developing countries. Therefore other 
simple clinical or laboratory parameter to monitor therapy is essential in developing 
countries.‖ 
 
OTHER TESTS 
―A variety of other laboratory tests have been studied as potential markers of HIV 
disease activity. Among these are quantitative culture of replication – component HIV 
from plasma , peripheral blood mononuclear cells , or resting CD4 T cells , circulating 
levels of β2microglobulin , soluble IL-2 receptor, Ig A , acid labile endogenous 
interferon orTNF a and the presence or absence of activation markers such as CD38, 
HLA-DR. Though these are the markers of disease activity, they do not play a major 
role in monitoring of patients with HIV infection.‖ 
―Hence in our study various clinical and inexpensive laboratory measures such as 
clinical staging WHO , total lymphocyte count (TLC), haemoglobin , absolute 
lymphocyte count (ALC) were done to assess HIV disease activity and compared with 
CD4 count. Then , it was analysed that these parameters may be used as a surrogate 
marker for CD4 cell count to initiate ART and to monitor therapy.‖ 
 
 
 CLINICAL MANIFESTATIONS 
―The clinical consequences of HIV infection encompass a spectrum ranging from an 
acute syndrome associated with primary infection to a prolonged asymptomatic state 
to advanced disease. It is best to regard HIV disease as beginning at the time of 
primary infection and progressing through various stages.‖ 
ACUTE HIV SYNDROME 
 
PERSISTENT GENERALISED LYMPHADENOPATHY 
 
 
―It is unknown how many individuals infected with HIV will have signs and 
symptoms of an acute viral infection.This illness is similar to Infectious 
mononucleosis and presents with fever, myalgia, nausea, and pharyngitis 1to 8 week   
after exposure. On examination, macular rash, athralagia, oral ulceration, 
lymphadenopathy and occasional hepatosplenomegaly can be noted. Some cases 
present with symptoms of aseptic meningitis, fever, headache, meningismus and 
photophobia. CSF pleocytosis can be present and HIV has been detected in CSF. The 
acute illness resolves spontaneously after 1 to 2 weeks and is diagnosed by the 
presence of an HIV core antigen called p24 in the serum.Following this acute illness, 
patients can remain in a latent asymptomatic state for years.‖ 
―Some HIV-infected individuals develop persistent generalized lymphadenopathy. 
This entity is a frequent early clinical sign of HIV infection and appears to follow 
seroconversion in 50% of individuals.‖ 
 
 
 
ASYMPTOMATIC STAGE – CLINICAL LATENCY 
 
―The length of time from initial infection to the development of clinical disease varies 
for a period of 10 years.HIV disease with active viral replication is ongoing and 
progressive during this period. The middle chronic phase represents a stage of relative 
containment of the virus. The immune system is intact at this point but there is 
continued HIV replication that may last for several years. Patients either are 
asymptomatic or develop persistent lymphadenopathy and many patients have minor 
opportunistic infections. During this phase , viral replication in the lymphoid tissue 
continues unabated. The extensive viral turn over is associated with continued loss of 
CD4 Cells , but there is replenishment of CD4 cells .So the loss is modest.‖ 
 
 
 
 
 
SYMPTOMATIC DISEASE 
―Symptoms of HIV disease can appear at any time during the course of HIV infection. 
The spectrum of illnesses changes as the CD4+ T cell count declines. The more severe 
and life-threatening complications of HIV infection occur in patients with CD4+ T 
cell counts <200/μL. A diagnosis of AIDS is made in individuals age 6 years and 
older with HIV infection and a CD4+ T cell count <200/µL  and in anyone with HIV 
infection who develops one of the HIV -associated diseases considered to be 
indicative of a severe defect in cell mediated immunity. The causative agents of the 
secondary infections are opportunistic organisms such as P. jiroveci, atypical 
mycobacteria,CMV, and other organisms that do not ordinarily cause disease in the 
absence of a compromised immune system.‖ 
 
 
 
 
 
  
 
 
 
 
 
 
 
 
―The  proposed revisions of WHO staging are designed to 
 
 to guide decisions on when to start cotrimoxazole prophylaxis, start ART and other 
HIV related interventions‖ 
 
―provide simple guidance to assist clinical care providers on when to start, substitute, 
switch or stop ART in HIV-infected adults and adolescents, or to trigger referral as 
outlined in the WHO ART guidelines for a public health approach 
 
 be used to assess current clinical status of individuals in HIV care, either 
on or off ART‖ 
 
―encourage clinical care providers to offer diagnostic testing for HIV in adults and 
adolescents exhibiting the clinical events suggestive of HIV disease prompt urgent 
offer of HIV diagnostic testing for stage 3 or stage 4 events either on site, or by  
referral for testing to a site where immediate assessment by HIV care providers able to 
initiate ART can be performed‖ 
 
 ―be used to guide clinicians in assessing the response to ART, particularly where viral 
load and/or CD4 counts or percentages are not widely or easily available (new or 
recurrent stage 4 events may suggest failure of response to treatment; new or recurrent 
stage 2 or stage 3 events may suggest an inadequate response to treatment, potentially 
because of poor adherence; however further evidence is required in order to determine 
the significance of staging events once ART has commenced. Clinical events in the 
first three months after ART has begun may be caused by immune restoration 
syndrome (IRS) rather than a poor response to ART).‖ 
 
 
 
 
 
 HIV AND METABOLIC SYNDROME: 
―Prevalence of metabolic syndrome amonh hiv infected patients around 20%.Hiv 
causes dyslipidemia,increases triglycerides and very low density lipoprotein.Protease 
inhibitors also causes insulin resistance leading to metabolic syndrome.Hiv leads to 
lipodystrophy promoting visceral adiposity causing insulin resistance 
Due to increased prevalence of metabolic syndrome in hiv  they are more prone for 
cardiovascular disease,early atherosclerosis,diabetes related complications‖ 
 
HIV AND DIABETES: 
―HIV patients present with metabolic syndrome, altered glucose metabolism, 
dyslipidemia and lipodystrophy‖. 
―RISK FACTORS: These include advancing age, male gender, longer duration of 
HIV infection, high CD4 count, high viral burden, high body mass index, greater 
waist circumference or waist- to- hip ratio.‖ 
Impaired glucose tolerance, and insulin resistance are noted to precede weight loss in 
patients with HIV . Insulin resistance, rather than insulin deficiency, is usually 
implicated in the pathogenesis of diabetes in HIV-infected patients.  
―Autoimmune diabetes, however, has recently been reported to develop in some HIV-
infected patients after immune restoration during HAART. Three Japanese patients 
presenting with diabetes after receipt of HAART have been shown to develop 
antibodies to glutamic acid decarboxylase, at a time when CD4 counts shot up 
suddenly. The type of diabetes associated with HIV may be classified as type 2 
diabetes (T2DM), rather than T1DM.‖ 
―Concurrent use of opiates among Hiv infected patients  may alter beta cell function 
while heroin addiction is associated with insulin resistance. No specific mechanisms 
of action have been proposed for these effects.‖  
―HIV infection is linked with hepatitis C infection (HCV), which is associated with 
insulin resistance and diabetes, due to increased intrahepatic tumour necrosis factor 
(TNF α) and hepatic steatosis. These factors increase the risk of diabetes in a patient 
suffering from concurrent HIV and HCV infection. Persons with HCV who are 40 
years of age or older are greater than 3 times more likely to have diabetes than those 
of the same age without HCV infection.‖  
―HIV is also associated with various endocrine abnormalities, including those of the 
growth hormone axis. These include deficiency of growth hormone, as well as growth 
hormone resistance. Growth hormone deficiency may contribute to insulin resistance 
in HIV-infected patients‖  
―The increased accumulation of visceral fat, with wasting of subcutaneous fat, noted 
in these patients, creates higher levels of inflammatory cytokines such as TNF α. This 
in turn leads to diabetes or impaired glucose tolerance by increasing insulin 
resistance.HIV-infected patients with metabolic syndrome show disturbances in 
inflammation and adipokines: they have higher CRP  and leptin  and lower 
adiponectin . This may contribute to the pathogenesis of diabetes.‖ 
―Anti-retroviral drugs are not the only iatrogenic culprits in HIV-associated diabetes. 
Drugs used to manage comorbid conditions associated with AIDS may also cause 
diabetes. Pentamidine, which is used to prevent and treat P. carinii associated 
pneumonia, can cause β-cell toxicity, with acute hypoglycemia followed by later 
diabetes .Megesterol acetate, which is used as an appetite stimulant, predisposes to 
diabetes because of its intrinsic glucocorticoid like activity, increased caloric intake 
and weight gain . Hypoglycemia has been noted to resolve once megesterol is stopped, 
and to recur on rechallenging.Patients on HAART may also be predisposed to diabetes 
because of the improved nutritional status and weight gain that accompanies effective 
treatment of HIV.‖ 
HIV AND CARDIOVASCULAR DISEASE: 
Dilated cardiomyopathy 
Myocarditis 
Autoimmune cardiomyopathy 
Nutritional related cardiomyopathy 
Pericardial effusion 
Endocarditis 
Hiv associated pulmonary hypertension 
Vasculitis and coronary artery disease 
Hypertension 
Drug relaed cardiotoxicity 
 
―Hiv disease is an important cause of diated cardiomyopathy with an incidence of 
about 15.9 in 1000  before HAART.Mortality was higher in patients having depressed 
left ventricular fractional shortening or increased left ventricular 
dimension,thickness,mass,wall stress,heart rate,blood pressure.‖ 
 
HIV AND NEUROLOGICAL DISEASE: 
BRAIN (FOCAL) 
Cerebral toxoplasmosis 
Primary CNS  lymphoma 
Progressive multifocal leucoencephalopathy 
Cryptococoma 
Tuberculoma 
Varicella zoster encephalitis 
NON FOCAL 
Hiv associated neurocognitive disorders  
Toxoplasmosis 
Cytomegalovirus 
Herpes encephalitis 
Metabolic encephalopathy 
Brain abscess 
MENINGES: 
Aseptic meningitis 
Tuberculous meningitis 
Syphilitic meningitis 
Cryptococcal meningitis 
Metastatic meningitis 
SPINAL CORD: 
Vacuolar myelopathy 
Varicella related myelopathy 
Metastatic myelopathy 
distal sensory polyneuropathy 
autonomic Cytomegalovirus myelopathy 
Vitamin B 12 related myelopathy 
PERIPHERAL NERVES AND NERVE ROOTS: 
Acute inflammatory demyelinating polyradiculoneuropathy 
chronic inflammatory demyelinating polyradiculoneuropathy 
vasculitic neuropathy 
brachial plexopathy 
lumbosacral plexopathy 
cranial mononeuropathy 
neuropathy 
drugs incuded neuropathy 
MUSCLE: 
Polymyositis 
Pyomyositis 
Inclusion body myositis 
Zidovudine myopathy 
AIDS cachexia myopathy 
TREATMENT RELATED IMMUNE RECONSTITUTION INFLAMMMATORY 
SYNDROME 
 
 
 
TB REACTIVATION BY HIV: 
―The depletion of CD4+ T cells, which is a main feature of AIDS, is certainly an 
important contributor to the increased risk of reactivation of latent TB and 
susceptibility to new M.tuberculosis  infection. .Other mechanisms reported to 
facilitates infection and disease in individuals with HIV are up-regulation of 
tuberculosis bacteria entry receptors on macrophages , HIV manipulation of 
macrophage bactericidal pathways , deregulated chemotaxis, and a tipped Th1/Th2 
balance. It has also been shown that HIV impairs tumor necrosis factor (TNF)-
mediated macrophage apoptotic response toM.tuberculosis and thus facilitates 
bacterial survival‖. 
―In the latent phase of TB, Several immune mechanisms, such as increased levels of 
FoxP3
+
 Treg cells, increased production of IL-27 , TGF-β , PGE-2 ,SOCS1, or the 
decoy receptor D6, or diminished levels of IFN-γ, TNF, and polyfunctional specific T 
cells, are believed to play a role in such reactivation. Many of these factors, such as 
SOCS1 or IL-27, down-regulate the IFN-γ/IL-12 axis, thereby impairing bacterial 
control, while others, such as the D6 decoy receptor, are mainly anti-inflammatory, 
but may indirectly inhibit efficient bacterial clearance.‖ 
―Granulomas are organized cellular structures that constitute TB's pathologic 
hallmark.. CD4
+
 T cells and TNF are important in maintaining granuloma 
organization. Granuloma formation may fail in individuals with a compromised 
immune system, and there are several hypotheses about how HIV exacerbates TB 
pathology through the manipulation of granulomas‖  
―Specifically, TB patients with AIDS present a dominant granulocytic infiltrate and 
necrosis without the typical caseous necrosis seen in non-HIV-infected TB 
granulomas. This has been associated with the killing of CD4
+
 cells in the granuloma, 
probably resulting in a direct disruption of granuloma structure and abolition of the 
containment of infection. Cavitary lesions are seldom encountered in patients with a 
CD4 T-lymphocyte count <200/mm
3
.As a result, while in the majority of adult 
patients TB is confined preferentially to the lungs, in HIV-infected patients TB can be 
a systemic disease involving multiple organs that lack well-defined granulomas and 
instead develop more diffuse lesions .All forms of extrapulmonary TB have been 
described in patients with HIVIN‖ 
―While TNF production in response to M. tuberculosis infection is required for control 
of bacterial growth, TNF is known to activate HIV replication in macrophages  
indicating that the host immune response initiated against one pathogen may promote 
the replication of another. Thus, both HIV and M. tuberculosis stimulate TNF release 
from infected cells, and TNF hampers bacterial growth while enhancing HIV 
replication.‖ 
―It has been suggested that TB patients have a microenvironment that facilitates HIV 
infection by 
 increasing the expression of co-receptors CXCR4 and CCR5 
 increasing pro-inflammatory cytokines, especially TNF; and iii) down-regulation of 
CCL5 . It has also been shown M tuberculosis and its cell wall component, 
lipoarabinomannan (LAM)  may activate replication of HIV in provirus-carrying cells 
by inducing TNF and IL-6 production through the NF-κB pathway, which in turn 
triggers transcriptional activation of the long terminal repeat (LTR) promoter and 
supports replication of  HIV.‖ 
IMMUNE RECONSTITUTION INLAMMATORY SYNDROME: 
―A particularly intriguing phenomenon is immune reconstitution inflammatory 
syndrome (IRIS). IRIS may develop in M tuberculosis and HIV co-infected patients 
who undergo anti-TB treatment and antiretroviral therapy (ART) . The patients 
present with an exacerbation of symptoms and radiological manifestations of TB, and 
recognized predictors of IRIS include low CD4
+
 T lymphocyte counts and high 
plasma viral load prior to initiation of ART, and an increase in CD4
+
 counts after 
highly active antiretroviral therapy (HAART) onset. Possible mechanisms responsible 
for IRIS may be a sustained Th1-response against mycobacterial antigens, which is 
followed by dysregulation of cytokine secretion and T cell migration to the 
inflammatory site . Recently, it was shown that patients who developed IRIS had 
higher pre-ART levels of TNF and increasing levels of inflammation 
biomarkers.Moreover, it has been demonstrated that TB/HIV co-infected patients who 
experienced IRIS had significantly lower levels of Abs to the phenolic glycolipid 
(PGL-TB1) antigen, specific form M tuberculosis compared to patients who did not 
develop TB-IRIS.‖ 
HIV AND CANCER: 
20% total death in hiv infected patients were cancer releated 
Common cancers in hiv: 
Kaposis sarcoma 
Non-hodgkins lymphoma 
Hodgkin lymphoma 
Cervical cancer 
CNS lymphoma 
Immunoblastic lymphoma 
Burkitt‘ lymphoma 
Anal cancer 
Hepatocellular carcinoma 
Lung carcinoma 
Prostate carcinoma 
Oral cancer 
Leiomyosarcoma 
 
RISK FACTORS: 
Human papilloma virus infection 
Human herpes virus 8 infection 
Ebstein barr virus infection 
Hepatitis c coinfection 
Smoking 
 
 
  
HIV AND HEPATITIS C CO INFECTION: 
 
―The prevalence of hepatitis C in hiv infected patients around 20-30%.the main source 
of infection is blood borne route through iv needle sharing.following acute hepatitis C 
infection90% will develop chronic disease.this is significantly higher than the risk of 
chronicity among those with hepatitis C monoinfection where than 30% will 
spontaneously clear the virus.‖ 
 
HIV EFFECT ON CHRONIC HEPATITIS C: 
―Hiv infection has been associated with persistent HCV viral load,and reduced 
response to treatment.hiv virus causes quantitative loss of memory cells which is 
responsible for elevated HCV RNA level.hiv itself mediates hepatic cytokine release 
through tat ,gp 120.hiv infection makes hepatic fibrosis much earlier than those who 
were affected only by HCV.‖ 
 
 EFFECT OF HCV INFECTION ON  HIV: 
―HIV infection is linked with hepatitis C infection (HCV), which is associated with 
insulin resistance and diabetes, due to increased intrahepatic tumour necrosis factor 
(TNF α) and hepatic steatosis. These factors increase the risk of diabetes in a patient 
suffering from concurrent HIV and HCV infection. Persons with HCV who are 40 
years of age or older are greater than 3 times more likely to have diabetes than those 
of the same age without HCV infection‖ 
―Hiv patients are more prone for fatty liver disease,hepatocellular 
carcinoma,metabolic syndrome,vasculitic syndromes when they are co infected with 
hepatitis C virus.‖ 
 
 TOTAL LYMPHOCYTE COUNT 
―TLC is easily obtained from the routine blood count with differential through 
multiplication of lymphocyte percentage by white blood cell count. 
 
TLC= % OF LYMPHOCYTE × TOTAL WBC COUNT 
  TLC has been suggested as a measure of when to initiate both HAART and 
prophylaxis against opportunistic illness in resource limited settings. In December 
2003, the WHO issued the recommendations for the initiation of ART, when CD4 
testing unavailable to include WHO stage 3 or 4 or WHO stage 2 in combination with 
the TLC<1200 cells/cu.mm ― 
 
―CAROLINE COSTELLO, MPH, KENRAD E. NELLSON, MD conducted a study 
in Thai population  on ― Predictors of low CD4 count in resource limited settings‖. In 
this study TLC<1200cells/cu.mm has good corelation  with CD4<200cells/µL 
improved the sensitivity above that of meeting the WHO guidelines for onset of ART 
while maintaining a specificity above 99%.‖ 
 
―S.M. ALAVI, F. AHMADI et al conducted a study on ―corelation between total 
lymphocyte counts, haemoglobin, hematocrit and CD4 count in HIV/AIDS patients‖ 
in this study a strong correlation was observed between CD4 counts and TLC.‖ 
 
ANAEMIA 
 
―Disorders of hematopoietic system including lymphadenopathy, anaemia, leucopenia 
and /or thrombocytopenia are common throughout HIV infections and maybe the 
direct results of HIV, manifestations of secondary infections, neoplasms or side 
effects of therapy.‖ 
―Anaemia is most common hematological abnormality in HIV infected patients. 
Among the specific reversible causes of anaemia in the settings of HIV infections are 
drug toxicity, systemic fungal and mycobacterial infections, nutritional deficiencies 
and parvo virus B19 infections. Folate levels are usually normal in HIV infected 
individuals. Vitamin B12 may be depressed as a result of achlorhydria or 
malabsorption‖. 
 
―True autoimmune anaemia is rare. Erythropoietin levels in patients with HIV 
infection and anaemia are generally less than expected given the degree of anaemia. 
Treatment with erythropoietin at doses of 100µg/kg thrice weekly may result in 
increase in haemoglobin.‖ 
 
―BELPERIO PS, RHEW DC. Prevalence and outcomes of anaemia in individuals 
with human immunodeficiency virus. In this study it was found that anaemia was 
more commonly associated with disease progression with progressive decrease in 
CD4 count.‖ 
 
―MOCROFT A, KIRK O, BARTON SE, et al conducted a study on ― anaemia is 
independent predictive marker for clinical prognosis in HIV infected patients‖ from 
across Europe. In this study it was found that anaemia was independent predictor of 
mortality in HIV infected patients.‖ 
INITIAL EVALUATION OF THE PATIENT WITH HIV INFECTION: 
―History and physical examination 
Routine chemistry and haematology  
Liver function test 
Lipid profile test 
CD4 T lymphocyte count 
Plasma HIV RNA level 
HIV resistance testing 
HLA-B5701 screening 
Rapid plasma regin test& veneral disease research laboratory 
Anti toxoplasma antibody titer 
Purified protein derivative 
Mini mental status examination 
Serology test for hepatitis A,B,C.‖ 
INDICATIONS FOR CHANGING ANTI RETRO VIRAL THERAPHY: 
Less than a 1 log drop in plasma HIV RNA by 4 weeks following the initation of 
therapy 
A reproducible significant incresase (defined as three fold or greater) from the nadir of 
plasma HIV RNA level not attributable to intercurrent infection,vaccination,or test 
methodology 
Persistently declining  CD4 T cell numbers 
Clinical deterioration 
Side effects 
ANTI RETROVIRAL THERAPY: 
NUCLEOSIDE REVERSE TRANSCRITASE INHIBITORS 
 Abacavir 
Didanosine 
Emtricitabine 
Lamivudine 
Stavudine 
Zidovudine 
NUCLEOTIDE REVERSE TRANSCRIPTASE INHIBITORS: 
Tenofovir 
NON NUCLEOSIDE REVERSE TRANSCRIPTASE INHIBITORS: 
Delavirdine 
Efavirenz 
Etravirine 
Nevirapine 
Rilpivirine 
PROTEASE INHIBITIRS: 
Fosamprenavir 
Indinavir 
Lopinavir 
Nelfinavir 
Ritonavir 
Saquinavir 
Atazanavir 
Darunavir 
Tipranavir 
ENTRY INHIBITORS: 
Enfuvirtide 
Maraviroc 
INTEGRASE INHIBITORS: 
Raltegravir 
Elvitegravir 
Dolutegravir. 
 
ADVERSE EFFECTS OF ANTI RETRO VIRAL THERAPY: 
―Zidovudine-anemia,neutropenia,lipoatrophy,lactic acidosis 
Abacavir-hypersensitive rash 
Didanosine-pancreatitis,neuropathy,fulminant hepatic failure 
Stavudine-lactic acidosis,lipoatrophy 
Tenofovir-osteoporosis,fanconi syndrome,hypokalemia 
Nevirapine-rash ,hepatotoxicity 
Efavirenz-rash ,neropsychiatric symtoms 
Indinavir-renal stones 
Nelfinavir-diarrhea 
Atazanavir-gall stones and renal stones 
Tipranavir-intracranial bleed 
Protease inhibitors-lipodystrophy,diabetes,dyslipidemia.‖ 
 
 
 
 
 
 
 
 
  AIMS AND OBJECTIVES OF THE STUDY 
 
1.To evaluate the correlation of CD4 counts with the TLC and ALC to suggest that 
these can be used as a surrogate for CD4 count to initiate ART in resource limited 
settings. 
 
2. To determine a range of TLC and ALC cut-offs for predicting CD4 count <350 
cells/μl, which is important for the initiation of ART. 
 
 
 
 
MATERIALS AND METHODS; 
STUDY POPULATION: 
The present study is  conducted on HIV seropositive patients admitted in any wards or 
attending outpatient departments  of  Government Rajaji Hospital, Madurai during the 
period of  Jan2016 to June 2016. 
 
INCLUSION CRITERIA: 
The individuals should be above 18 years of age, they should be proven to be HIV-
positive and they should not be on prior anti-retroviral therapy (ART). 
 EXCLUSION CRITERIA:  
HIV patients on prior ART  
HIV patients who are Pregnant. 
Paediatric HIV patients. 
HIV Patients on steroid , iron , or vitamin therapy. 
HIV Patients with bleeding disorder. 
HIV patients with Chronic renal failure patients. 
HIV Patients with opportunistic infections or any intercurrent infection likely to alter 
the lab parameters. 
 
DESIGN OF STUDY: 
Cross sectional study 
 
PERIOD OF STUDY: 
January2016 To June  2016 ( 6 months) 
 
 
COLLABORATING DEPARTMENTS: 
ART Centre  
Department of Biochemistry 
Department of Microbiology. 
ETHICAL CLEARANCE:  
Necessary ethical clearance was obtained from ethical committee ,GRH , Madurai. 
CONSENT: Individual written and informed consent. 
ANALYSIS:STATISTICAL ANALYSIS. 
CONFLICT OF INTEREST: NIL 
FINANCIAL SUPPORT:  SELF 
PARTICIPANTS: 
HIV seropositive patients admitted in any wards or attending outpatient departments  
of  Government Rajaji Hospital, Madurai during the period of  Jan 2016 to June 2016. 
DATA COLLECTION: 
A previously designed proforma is used to collect the demographic and clinical 
details of the patients. All the patients underwent detailed clinical evaluation, 
appropriate investigations. 
History was taken on details of unprotected sexual intercourse , blood transfusion 
,IV drug abuse, repeated respiratory infections,fever , recurrent diarrhoea and 
unexplained weight loss. Presence of lymphadenopathy, oral ulcers, splenomegaly 
and peripheral neuropathy will be noted. Hemoglobin, ,complete blood count 
including total WBC count and differential count , blood urea, serum creatinine, 
blood glucose, liver function tests including serumbilirubin, serum transaminases, 
will beestimated. CD4 count , Total lymphocyte count and absolute lymphocyte 
count are also estimated .The study group was divided on the basis of CD4 count  
 into 200 to 350 cells/cu.mm and to <200 cells/cu.mm. various cut offs for absolute 
lymphocyte count and total lymphocyte count was  studied in these groups. And a 
range of absolute lymphocyte count and total lymphocyte count cut offs for CD4 
count <350 cells/cu.mm was determined which can be used to initiate 
antiretroviral therapy in resource limited settings. 
 
LABORATORY INVESTIGATIONS: 
The following specific investigations were done  
1.Hemoglobin 
2.Complete blood count including total WBC count and differential count 
3.CD4 count 
4. absolute lymphocyte count and total lymphocyte count. 
 
CD4 COUNT : 
CD4 count was done using flowcytometry . flow cytometers use lasers to excite 
fluorescent antibody probes specific for various cell surface markers , such as CD3, 
CD4 , and CD8. It is calculated in cells/µL. 
AUTOMATED CELL COUNTER 
Total WBC count , Differential count , haemoglobin ,were obtained using automated 
cell counter. 
Automated cell counters sample the blood , and quantify and describe the cell 
populations using both electrical and optical techniques.  
Total lymphocyte count was easily obtained from total WBC count and differential 
percentage of lymphocyte using the following formula 
TLC=% of lymphocyte × total WBC count. 
Normal TLC is usually >1800 cells/cu.mm. 
 
LIMITATIONS OF OUR STUDY 
1.WHO clinical staging were done on presumed clinical basis and some basic 
laboratory investigations . so , some patients may be wrongly staged. 
2.Small sample size of the study. 
3.Asymptomatic HIV patients with opportunistic infections could not be identified 
and could have masked the alterations in total lymphocyte count as well as CD4 
count. 
 
STATISTICAL TOOLS  
The information collected regarding all the selected cases were recorded in a master 
chart. Data analysis was done with the help of computer using epidemiological 
information package. 
Using this software range, frequencies , percentage , mean , standard deviations , chi 
square and ‗p‘ values were calculated. Kruskul wallis chi square test was used to test 
the significance of difference between quantitative variables and Yate‘s test for 
qualitative variables. A ‗P‘ value less than 0.05 denotes significant relationship. 
 
 
RESULTS 
The study population includes 100 patients. 
 
TABLE 1 : AGE DISTRIBUTION 
AGE GROUP NO.OF CASES % 
<20 3 3 
21-30 20 20 
31-40 54 54 
41 - 50 17 17 
> 50  6 6 
Total  100 100 
 
In our study about 54% of patients were in age group between 31-40 years . 91% 
of patients are in age group between 21-50 years. So majority of patients in our 
study were in reproductive age group. 
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TABLE 2 : GENDER DISTRIBUTION 
 
SEX NO.OF CASES 
MALE 67 
FEMALE 33 
Total  100 
 
In our study about 67% of patients were males and 33 % were females. 
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TABLE 3 : EXPOSURE TYPE: 
RISK FACTOR NO.OF CASES 
Heterosexual 83 
Homosexual 12 
Unknown 5 
Total  100 
 
The above table shows that the heterosexual mode of transmission was the commonest 
mode of transmission accounting for 83 % of the cases. Around 12 % of cases 
transmission was through homosexual route esp(male to male transmission). 
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 TABLE 4: CLINICAL STAGING AND NO. OF CASES  
CLINICAL STAGING NO.OF CASES 
I 29 
II 31 
III 18 
IV 22 
Total  100 
As shown in the above table , about 60% of the patients came under WHO stage 1 and 
2 and 40% came under WHO stage 3 and 4.  
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 TABLE 5: DISTRIBUTION OF CD 4 COUNT 
 
CD4 COUNT 
NO.OF 
CASES 
< 100  6 
101 - 200   23 
201 - 350 52 
> 350    19 
Total  100 
 
The CD 4 counts were grouped under four different headings. They are <100 cells/µl, 
101-200 cells/µl, 201-350 cells/µl and >350 cells/µl.  
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 TABLE 6 : CD4 COUNT AND CLINICAL STAGING: 
 
CLINICAL 
STAGING MEAN SD 
I 381.28 148.49 
II 243.87 95.91 
III 281.72 98.24 
IV 155.86 69.77 
 
Stage 4 had the lowest mean CD4 count (155.86/µL) among all stages. Stage 1 had the 
highest mean CD4 count (381.28/µL) when compared to all stages. Stage 2 had mean 
CD4 count of 243.87/µL and stage 3 had CD4 count of 281.72/µL. 
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TABLE  TOTAL LYMPHOCYTE COUNT(TLC) AND CLINICAL STAGING 
 
CLINICAL 
STAGING MEAN SD   
I 1809 363.29   
II 1613.83 331.76 <0.001 
III 1584.03 301.72   
IV 1275.96 284.06   
 
Stage 4 had lowest mean TLC  of 1275.96 cells/cumm. Stage 1 had the highest mean 
TLC of 1809 cells. Stage 2 had mean TLC of 1613.83 cells and stage 3 had mean TLC 
of  1584.03 cells. 
 
TABLE HEMOGLOBIN AND CLINICAL STAGING: 
CLINICAL 
STAGING MEAN SD   
I 9.82 1.04   
II 7.34 1.39 <0.001 
III 6.79 1.34   
IV 5.29 1.12   
 
Stage 4 had lowest mean haemoglobin of 5.29g and stage 1 had highest mean 
haemoglobin of 9.82 gm . stage 2 had mean haemoglobin of 7.34gm and stage 3 had 
mean haemoglobin of 6.79gm. 
 
  
TABLE  ABSOLUTE LYMPHOCYTE COUNT AND CLINICAL STAGING 
 
CLINICAL 
STAGING MEAN SD   
I 1284.03 120.48   
II 1226.04 147.99 <0.001 
III 1196.11 177.05   
IV 1095.00 142.79   
 
The mean absolute lymphocyte count in stage 4 was 1095 cells , in stage 1 was 1284 
cells , in stage 2 was 1196.4 cells and in stage 3 was 1196.45 cells. 
 
TABLE MEAN PATTERN OF STUDY PARAMETERS WITH CD4 COUNTS 
 
  TLC   HB   ALC   
  Mean SD Mean SD Mean SD 
< 100 (6)  924.833 
106.92
5 5.633 1.46 904.833 157.093 
101 - 200 
(23)   
1223.26
1 
208.64
5 5.639 1.159 
1052.69
6 96.303 
 201 - 350  
(52)  
1651.21
2 
150.68
3 7.59 1.647 
1242.15
4 91.271 
> 350   (19) 
2059.94
7 
241.39
9 9.774 1.634 
1353.36
8 94.004 
P VALUE < 0.001 SIG < 0.001 SIG < 0.001 SIG 
 
 In our study the Total Lymphocyte Count, absolute lymphocyte count and 
hemoglobin  showed an upward trend with CD 4 count.  
  
The mean TLC for CD4 count less than 350 cells/µL is 1266.4 cells/cu.mm. and mean 
TLC for CD4 cont less than 200 cells/µL  is 1074.05 cells/cu.mm. 
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The mean Hemoglobin for CD4 count <350 cells/µL  is 6.26 gm and the mean 
haemoglobin for CD4 count <200 cells/µL  is 5.6 gm 
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The mean ALC for CD4 count <350 cells/µL  is 1066.56 cells/cu.mm. and the mean 
ALC for CD4 count <200 cells/µL  is 978.75 cells/cu.mm. 
 
DISCUSSION: 
 
―If CD4 count is available and HIV infected patient‘s CD4 lymphocyte count is less 
than 200 cells/µL , it would be universally agreed that ART should be initiated 
regardless of the fact that CD4 counts have biologic variability by sex , age , and 
ethinicity as well as some variability in measurement in the laboratory.‖ 
―Although the CD4 count has become the gold standard but in resource limited 
seetings where the CD4 count is not routinely available , other clinical and laboratory 
0.0
200.0
400.0
600.0
800.0
1000.0
1200.0
1400.0
< 100 (6) 101 - 200
(23)
 201 - 350
(52)
> 350
(19)
904.8 
1052.7 
1242.2 
1353.4 
CD4 VS ALC 
ALC
parameters can be predictive of severe immune compromise. Routine hemotologic 
testing is inexpensive and widely accessible and can provide measurements of the 
TLC and haemoglobin level.‖ 
―In our study about 100 patients are randomly enrolled , of which 67% are males and 
33% are females. Most of the patients are in the reproductive age group. 74% of the 
patients are in the age group between 21-40 years. This shows that HIV is more in 
reproductive age group. This indicates a trend of young and productive generation 
being affected; a reflection of the devastating effects india will face as the younger 
generation work force is affected.‖ 
In this study age and type of exposure are also studied and correlated  with CD4 count 
. ―The most common mode of transmission is heterosexual route (83%). This is in 
consistent with UZAGARE R et al who found that the percentage of various mode of 
transmission as sexual route (93%) commonly heterosexual , blood (2.32%) , 
perinatal(2.32%) , surgery and IV needles (3.72%). This is also similar to the findings 
in studies by A.R.Sircar et al (64% heterosexual), A.D Harris (62% heterosexual) and 
Kothari et al (68%heterosexual).‖ 
 
STAGING: 
WHO in 2005 proposed a revised clinical staging to initiate ART in resource limited 
settings especially in Africa and Asia. 
 
CLINICAL AND IMMUNOLOGICAL CRITERIA FOR INITIATING ART IN 
ADULTS AND ADOLESCENTS 
CLINICAL STAGE ART 
STAGE 4 Treat 
STAGE 3 Consider treatment CD4 if available can 
guide the urgency with which ART should 
be started  
STAGE 1 , 2 Only if CD4 <350cells/µL 
 
―Many studies were conducted to asses the WHO recommendation for clinical criteria 
to initiate ART in resource limited settings.‖ 
―In our study using WHO clinical staging 4 when correlated with CD4 count < 200 
cells/µL  we get a significant statistical  p value. Patients with stage 4 had mean CD4 
count 155.86 cells/µL and patients with CD4 count < 200 cells/µL were in stage 3 or 
stage 4(93%)‖ 
 
 
Comparison of distribution according to CD 4 counts in different studies    
 
 
CD4 
counts  
Our study  
(n=50)  
Beck 
(n=153)  
John Hopkins 
study  
(n=5864)  
YRG study  
(n=1315)  
<100  6(6.0%)  12 (13%)  1055(18%)  105(8%)  
101-200  23(23.0%)  53 (34%)  1584(27%)  395(30%)  
201-350  52(52.0%)  78 (53%)  3225(55%)  905(62%)  
 
TOTAL LYMPHOCYTE COUNT 
―In December 2003 , the WHO broadened the recommendations for initiation of ART 
when CD4 testing is unavailable. Many studies have evaluated the use of TLC as a 
surrogate marker for CD4 cell count with mixed results.  In our study the mean TLC 
for CD4 count less than 350 cells/µL is 1266.4 cells/cu.mm. and mean TLC for CD4 
cont less than 200 cells/µL  is 1074.05 cells/cu.mm. CAROLINE COSTELLO, MPH , 
KENRAD E. NELSON , MD , conducted a study on predictors of low CD4 count in 
resource limited settings. In this study TLC<1200 cells/cu.mm correlated with CD4 
count <200 cells/µL. In a study ―complete blood count as a surrogate CD4 cell marker 
for HIV monitoring in resource limited settings‖ by  RAY Y. CHEN , MD , 
ANDREW O. WESTFALL , MSJ . MICHAEL HARDIN also showed correlation of 
TLC <1200 cells/cu.mm to CD4 count <200 cells/µL.‖  
―In our study TLC<1100 cells/cu.mm correlates with CD4 count <200 cells/µL and 
TLC < 1300 cells/ cu.mm correlates with CD4 count <350 cells /µL. As CD4 count 
<350 cells/mm
3
 is used as a cut off for anti-retroviral therapy, we further evaluated for 
a correlation between TLC and CD4 count <350 cell/mm
3
 and found a correlation 
between TLC < 1300 for CD4 count <350 cells/µL. Similar higher TLC cutoff values 
have been used in studies by Jacobson et al.where he used a TLC <1900 cells/mm
3
 as 
cut off to predict CD4 count <350cells/mm
3
. Kumaraswamy and his colleagues 
observed that with a TLC, <1400 cells/mm
3
, 73% of patients with CD4 cell counts 
<200 cells/mm
3
  were identified. With a TLC <1700 cells/mm
3
, 70% of patients with 
a CD4 cell count of <350 cells/mm
3
, requiring initiation of therapy for opportunistic 
infection, were identified. In contrast, some studies have shown TLC to be an 
imperfect predictor of CD4 count.‖ 
―This decrease in CD4 count is directly reflected in total lymphocyte count . 
measurement of peripheral blood CD4 T lymphocyte is probably the most important 
laboratory assay for evaluation and monitoring of patients with HIV. The most 
common technique for measuring CD4 count in developed country setting is flow 
cytometry which uses lasers to excite fluroscent antibody probes specific for various 
cell surface markers such as CD3, CD4, CD8 , which distinguish one type of 
lymphocyte from other.‖ 
 
ANEMIA: 
―Anemia is more common in India . in our study 82% of the patients are anemic. 92% 
are females and 77% are males were anemic. Patients with Hb <5g% were having 
mean CD4 count of 149 cells/µL. Anemia very well correlated with CD4 count with a 
stastically significant p value‖. 
―BELPERIO PS, RHEW DC Prevalance and outcomes of anemia in individuals with 
human immunodeficiency virus. In this study it was anemia more commonly 
associated with the disease progression with progressive decline in CD4 count and 
anemia was more common in females when compared to males.‖ 
―CAROLINE COSTELLO , MPH , KENRAD E.NELSON,MD , Predictors of low 
CD4 count in resource limited settings . in this study also anemia was more common 
among females than males.When anemia combined with TLC the accuracy of the test 
is increased.‖ 
ABSOLUTE LYMPHOCYTE COUNT: 
―Studies done prior to 2005, showed a relationship between the declines in ALC and 
CD4 lymphocyte counts as a strong predictor for short term disease progression. Thus 
during the era of scarce availability of testing laboratories as well as prohibitive cost 
of CD4 testing, ALC became an acceptable surrogate marker of immune function. 
Two recent studies one by Nyawira GIthinji et al and other by Sreenivasan et al 
have again highlighted the existence of a relationship between ALC and CD4 
lymphocyte counts. Even these two studies reveal a weak-modest relationship 
between these two markers and definitely no capability of detecting immunological 
and virological failures likely to contribute of ART resistance. A similar study by Sen 
S et al, in 2011 did not validate ALC as an effective surrogate marker of CD 4 
lymphocyte counts‖.  
―In our study, a positive ALC change is shown to be a sensitive and specific marker of 
positive CD4 change. In our study , The mean ALC for CD4 count <350 cells/µL  is 
1066.56 cells/cu.mm. and the mean ALC for CD4 count <200 cells/µL  is 978.75 
cells/cu.mm.‖ 
 
 
 
 CONCLUSION: 
―1.Majority of patients in our study were in reproductive age group. This indicates a 
trend of young and productive generation being affected; a reflection of the 
devastating effects India will face as the younger generation work force is affected.‖ 
2.Most common mode of HIV transmission was heterosexual. Also there is a rise in 
transmission through male to male sexual contact. 
―3. In our study TLC<1100 cells/cu.mm correlates with CD4 count <200 cells/µL and 
TLC < 1300 cells/ cu.mm correlates with CD4 count <350 cells /µL‖ 
―4. In our study using WHO clinical staging 4 when correlated with CD4 count < 200 
cells/µL  we get a significant statistical  p value. Patients with stage 4 had mean CD4 
count 155.86 cells/µL and patients with CD4 count < 200 cells/µL were in stage 3 or 
stage 4(93%).‖ 
―5. The mean Hemoglobin for CD4 count <350 cells/µL  is 6.26 gm% and the mean 
haemoglobin for CD4 count <200 cells/µL  is 5.6 gm%.‖ 
―6. , The mean ALC for CD4 count <350 cells/µL  is 1066.56 cells/cu.mm. and the 
mean ALC for CD4 count <200 cells/µL  is 978.75 cells/cu.mm.‖ 
 
 
 
 SUMMARY 
―This study ― Utility of total lymphocyte count and absolute lymphocyte count as a 
surrogate marker for CD4 count to initiate ART‖ was conducted in 100 HIV positive 
patients who attended ART medical centre in Government Rajaji Hospital , Madurai 
from  January 2016 to June 2016‖. 
―In our study 100 patients were randomly selected of which 67% were males and 33% 
were females. Above 74% were in age group between 21 to 40 years showed a 
prevalence of disease in reproductive age group.‖ 
―In all the patients various clinical and inexpensive laboratory measures such as WHO 
clinical staging , Total lymphocyte count , Hemoglobin , Absolute lymphocyte count 
were done and correlated with CD4 count. It was analysed that these parameters can 
used as a surrogate marker for CD4 count to initiate HAART.‖ 
―In our study TLC<1100 cells/cu.mm correlates with CD4 count <200 cells/µL and 
TLC < 1300 cells/ cu.mm correlates with CD4 count <350 cells /µL. 
The mean Hemoglobin for CD4 count <350 cells/µL  is 6.26 gm% and the mean 
haemoglobin for CD4 count <200 cells/µL  is 5.6 gm% 
 The mean ALC for CD4 count <350 cells/µL  is 1066.56 cells/cu.mm. and the mean 
ALC for CD4 count <200 cells/µL  is 978.75 cells/cu.mm.‖  
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              PROFORMA 
 
Name: 
Age / Sex: 
IP / OP no: 
Occupation: 
 
Presenting complaints: 
H/o unexplained weight loss. 
H/o diarrhoea 
H/o fever for >1 month 
 
Past History: 
H/o , unprotected sexual intercourse, blood transfusion, tattoing, iv drug use,  
H/o CLD, DM, HT, CKD, CVD, DRUG INTAKE, THYROID 
DISORDERS,EPILEPSY,HEPATITIS.  
Personal history 
alcoholic/ non alcoholic 
smoker/ nonsmoker 
 
 
Clinical Examination: 
General examination 
 
 
 
 
 
 
Nutrition  
Consciousness 
Orientation 
Afebrile/Febrile 
Pallor/no pallor 
Cyanosis/ No cyanosis 
Clubbing/No clubbing 
Pedal edema / no pedal edema  
Vitals  Height  
Weight  
Temperature  
Pulse rate 
Blood pressure 
Respiratory rate 
Oxygen saturation 
Waist , Hip circumferences 
Body mass index (BMI) 
Eyes  
 
 
 
 
 
 
 
 
 
Ear / Nose 
 
 
 
 
 
 
 
 
 
Oral cavity 
 
 
 
 
 
Endocrine : thyroid  
 
 
 
 Lymph node 
Characteristics: 
⚬ Size (two dimensions, in millimeters) 
⚬ Consistency (hard, fluctuant, soft) 
⚬ Tenderness 
⚬ Mobility 
⚬ Definition (discrete, matted) 
⚬ Symmetry 
 
 
Node Sites: 
▪ Posterior cervical chain 
▪ Anterior cervical chain 
▪ Submandibular 
▪ Supraclavicular 
▪ Submental 
▪ Axillary 
▪ Epitrochlear 
▪ Inguinal 
▪ Femoral 
Lungs  
 
 
 
 
 
Heart  
 
 
 
 
 
Breast  
 
 
 
 
 
 
Abdomen  
 
 
 
 
 
 
Genitals / Rectum  
 
 
 
 
 
 
 
Extremities / Musculoskeletal 
 
 
 
Skin   
  
 
 
 
CNS 
 
 
 
 
 
 
Psychiatric 
 
 
 
 
 
 
 
Laboratory investigations: 
1.Hemoglobin,complete blood count. 
2.CD4 count 
3.Total lymphocyte count (TLC)  
4. Absolute lymphocyte count (ALC). 
 
Diagnosis 
 
 
 
 
 
 
 LIST OF ABBREVIATIONS: 
HIV: Human immunodeficiency virus. 
AIDS: Acquired immune deficiency syndrome. 
CD4: Cluster differentiation 4 
TLC: Total lymphocyte count 
ALC: Absolute lymphocyte count. 
Hb: Hemoglobin. 
WHO: World health organisation. 
ART: Anti Retroviral therapy. 
PCR: Polymerised chain reaction. 
EIA : Enzyme immune assay. 
 
 
 
 
 
 
 
 
  
                                                  MASTER CHART  
ART NO. AGE SEX RISKFACTOR CLINICALSTAGING CD4COUNT TLC Hb ALC 
865/16 48 M HS  III  100 989 5.6 876 
866/16 38 M HS III 98 809 7.8 788 
867/16 49 M HS II 187 1487 6 877 
868/16 32 M HS II 310 1678 8 1200 
869/16 56 M HS IV 224 1189 4.5 1221 
870/16 36 M HS I 388 1689 10 1121 
871/16 32 F HS III 234 1800 5.5 1109 
872/16 54 M MSM I 345 1765 9.8 1278 
873/16 35 M HS IV 55 767 4.5 677 
874/16 32 M HS IV 244 1654 4.6 1123 
875/16 32 M MSM III 296 1734 7.9 1109 
876/16 54 M HS I 137 1432 8 990 
877/16 32 F U II 162 1324 6.5 1009 
878/16 23 M MSM II 414 2455 8.7 1433 
879/16 39 M HS II 212 1675 7.6 1143 
880/16 39 F HS I 650 2234 11 1433 
881/16 28 M HS IV 125 1265 3.3 1006 
882/16 36 M U II 250 1650 6.6 1232 
883/16 39 F HS I 620 2245 10 1311 
884/16 34 M HS IV 208 1762 5.6 1208 
885/16 36 F HS III 345 1609 7.9 1205 
886/16 28 M MSM II 321 1709 8 1250 
887/16 36 M MSM II 311 1804 8 1365 
888/16 34 M HS I 342 1245 9 1298 
889/16 25 M U I 303 1654 9.3 1309 
890/16 34 M HS I 243 1609 9.9 1324 
891/16 54 F HS III 284 1367 6.5 1365 
892/16 33 M HS II 234 1734 7 1321 
893/16 45 M HS I 213 1221 9 1114 
894/16 34 M HS II 112 1009 4.5 1076 
895/16 36 F HS I 543 2431 11 1344 
896/16 36 M MSM II 487 2211 8 1333 
897/16 38 M HS  I 564 2110 11 1321 
898/16 35 M U III 323 1788 7.8 1343 
899/16 26 M HS II 308 1877 7.5 1376 
900/16 19 F HS IV 126 1265 6.6 1007 
901/16 35 M HS III 254 1564 6.6 1310 
902/16 36 F HS I 223 1565 8 1321 
903/16 26 M U II 256 1655 7.6 1231 
904/16 38 M HS I 206 1676 8.8 1211 
905/16 23 M U I 306 1876 8.9 1309 
906/16 34 M HS IV 122 1345 6.3 1034 
907/16 36 F U III 317 1834 8.9 1387 
908/16 19 F HS II 114 1309 5.5 1012 
909/16 60 M U II 187 1323 4 1003 
910/16 36 F HS II 212 1678 6.5 1176 
911/16 33 M U IV 101 998 5.6 1004 
912/16 31 F HS I 234 1675 9 1212 
913/16 33 M MSM II 254 1609 4.5 1221 
914/16 28 M MSM II 234 1603 5 1208 
915/16 36 M HS II 208 1608 6 1200 
916/16 36 M HS III 267 1645 5.3 1278 
917/16 37 M HS IV 199 1342 5.6 965 
918/16 37 M HS II 176 1119 6.4 978 
919/16 43 M HS I 456 2187 10 1453 
920/16 46 F HS I 234 1678 8 1143 
921/16 24 F HS IV 218 1652 5.3 1100 
922/16 45 M MSM III 122 1023 7.5 1000 
923/16 27 F U II 133 1008 4.6 1008 
924/16 35 M HS II 234 1609 8 1342 
925/16 52 M HS I 342 1603 9 1456 
926/16 38 M HS IV 98 998 4.5 1113 
927/16 42 F HS I 654 2075 11 1432 
928/16 48 M U III 299 1699 6 1232 
929/16 36 F HS II 209 1655 8 1276 
930/16 44 M MSM I 348 1677 11 1290 
931/16 37 M HS IV 111 1000 4.7 1099 
932/16 24 M HS I 332 1654 10 1132 
933/16 43 M HS III 254 1632 6.8 1100 
934/16 39 M HS I 234 1678 10.8 1109 
935/16 29 F U II 338 1654 8.9 1387 
936/16 28 M HS II 388 1876 6.7 1354 
937/16 35 F HS IV 129 1611 4 1211 
938/16 45 M MSM III 432 2167 9.8 1309 
939/16 38 M U IV 211 1342 4.8 1123 
940/16 39 M HS  I 324 1678 9 1243 
941/16 46 M HS II 222 1698 6.6 1287 
942/16 42 F HS IV 131 1232 5.4 1208 
943/16 50 M HS II 166 1709 5.6 1009 
944/16 34 F U III 345 2000 6.7 1299 
945/16 26 F HS IV 94 999 4.4 987 
946/16 32 M HS I 544 2156 11.3 1389 
947/16 33 M HS I 578 2099 11.6 1420 
948/16 48 F HS II 343 1690 6.7 1287 
949/16 26 M HS I 541 2019 11 1243 
950/16 28 F HS IV 117 1200 4.5 1117 
951/16 42 M HS III 322 1655 7.8 1223 
952/16 35 M HS IV 356 1666 5.2 1432 
953/16 18 F U IV 120 1002 6.6 1223 
954/16 26 F U I 442 2111 9.9 1455 
955/16 32 F HS I 324 1765 9.6 1342 
956/16 39 F HS II 367 1698 9.7 1243 
957/16 24 F HS IV 111 1008 6 1111 
958/16 48 M HS III 456 2056 9.8 1454 
959/16 36 M U III 323 1678 8 1143 
960/16 29 M HS IV 222 1654 8.6 1121 
961/16 35 F HS II 111 1004 6.7 1265 
962/16 36 M MSM I 387 1654 10 1234 
963/16 37 F HS IV 107 1120 5.8 1000 
964/16 24 F U II 100 987 7 988 
 
TLC: Total lymphocyte count 
ALC: Absolute lymphocyte count. 
Hb: Hemoglobin 
 
 
 
 
 
 
 
  
 
  
 
                                              
 
 
 
                                                 
 
 
 
 
 
  
 
  
